Wenzhen Duan

List of Publications by Year
in descending order

71 papers	7,779 citations	66343 42 h-index	91884 69 g-index
74 all docs	74 docs citations	74 times ranked	9122 citing authors

#	Article	IF	Citations
1	A novel and accurate full-length HTT mouse model for Huntingtonâ€™s disease. ELife, 2022, 11, .	6.0	7
2	Ageâ€dependent cerebrospinal fluidâ€tissue water exchange detected by magnetization transfer indirect spin labeling MRI. Magnetic Resonance in Medicine, 2022, 87, 2287-2298.	3.0	6
3	Quantitative cerebrovascular reactivity<scp>MRI</scp>in mice using acetazolamide challenge. Magnetic Resonance in Medicine, 2022, 88, 2233-2241.	3.0	5
4	Impaired response of cerebral oxygen metabolism to visual stimulation in Huntingtonâ€™s disease. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 1119-1130.	4.3	5
5	Development of novel bioassays to detect soluble and aggregated Huntingtin proteins on three technology platforms. Brain Communications, 2021, 3, fcaa231.	3.3	11
6	Huntingtin silencing delays onset and slows progression of Huntingtonâ€™s disease: a biomarker study. Brain, 2021, 144, 3101-3113.	7.6	21
7	Early detection of Alzheimer's disease using creatine chemical exchange saturation transfer magnetic resonance imaging. NeuroImage, 2021, 236, 118071.	4.2	20
8	Abnormal Brain Development in Huntingtonâ€™ Disease Is Recapitulated in the zQ175 Knock-In Mouse Model. Cerebral Cortex Communications, 2020, 1, tgaa044.	1.6	11
9	Mutant G2019S-LRRK2 Induces Abnormalities in Arteriolar Cerebral Blood Volume in Mouse Brains: An MRI Study. Neurodegenerative Diseases, 2020, 20, 65-72.	1.4	1
10	Nemo-like kinase reduces mutant huntingtin levels and mitigates Huntingtonâ€™s disease. Human Molecular Genetics, 2020, 29, 1340-1352.	2.9	10
11	Transcriptional Assessment of Striatal mRNAs as Valid Biomarkers of Disease Progression in Three Mouse Models of Huntingtonâ€™s Disease. Journal of Huntington's Disease, 2020, 9, 13-31.	1.9	1
12	Differential Changes in Functional Connectivity of Striatum-Prefrontal and Striatum-Motor Circuits in Premanifest Huntingtonâ€™s Disease. Neurodegenerative Diseases, 2019, 19, 78-87.	1.4	19
13	Brain structure in juvenile-onset Huntington disease. Neurology, 2019, 92, e1939-e1947.	1.1	45
14	Small molecule modulator of protein disulfide isomerase attenuates mutant huntingtin toxicity and inhibits endoplasmic reticulum stress in a mouse model of Huntingtonâ€™s disease. Human Molecular Genetics, 2018, 27, 1545-1555.	2.9	38
15	2,4 DNP improves motor function, preserves medium spiny neuronal identity, and reduces oxidative stress in a mouse model of Huntington's disease. Experimental Neurology, 2017, 293, 83-90.	4.1	31
16	Mutant Huntingtin Disrupts the Nuclear Pore Complex. Neuron, 2017, 94, 93-107.e6.	8.1	274
17	Post-Translational Modifications (PTMs), Identified on Endogenous Huntingtin, Cluster within Proteolytic Domains between HEAT Repeats. Journal of Proteome Research, 2017, 16, 2692-2708.	3.7	48
18	Resting-state functional MRI reveals altered brain connectivity and its correlation with motor dysfunction in a mouse model of Huntingtonâ€™s disease. Scientific Reports, 2017, 7, 16742.	3.3	21

#	Article	IF	Citations
19	Mechanisms underlying neurodegeneration in Huntington disease: applications to novel disease-modifying therapies. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2017, 144, 15-28.	1.8	12
20	Metformin Protects Cells from Mutant Huntingtin Toxicity Through Activation of AMPK and Modulation of Mitochondrial Dynamics. NeuroMolecular Medicine, 2016, 18, 581-592.	3.4	40
21	The anti-dementia drug candidate, (â˜)-clausenamide, improves memory impairment through its multi-target effect. , 2016, 162, 179-187.		37
22	Characterization of Behavioral, Neuropathological, Brain Metabolic and Key Molecular Changes in zQ175 Knock-In Mouse Model of Huntingtonâ€™s Disease. PLoS ONE, 2016, 11, e0148839.	2.5	55
23	Early white matter abnormalities, progressive brain pathology and motor deficits in a novel knock-in mouse model of Huntington's disease. Human Molecular Genetics, 2015, 24, 2508-2527.	2.9	78
24	Metabolism in HD: Still a relevant mechanism?. Movement Disorders, 2014, 29, 1366-1374.	3.9	33
25	Sirtuin 1 activator <scp>SRT</scp>2104 protects Huntington's disease mice. Annals of Clinical and Translational Neurology, 2014, 1, 1047-1052.	3.7	40
26	Targeting Sirtuin-1 in Huntingtonâ€™s Disease: Rationale and Current Status. CNS Drugs, 2013, 27, 345-352.	5.9	36
27	Neuroprotective effects of <scp>PPAR</scp>â€Î³ agonist rosiglitazone in N171â€82Q mouse model of Huntington's disease. Journal of Neurochemistry, 2013, 125, 410-419.	3.9	98
28	Small-molecule TrkB receptor agonists improve motor function and extend survival in a mouse model of Huntington's disease. Human Molecular Genetics, 2013, 22, 2462-2470.	2.9	113
29	Sirtuins: from metabolic regulation to brain aging. Frontiers in Aging Neuroscience, 2013, 5, 36.	3.4	75
30	Transgenic Mouse Model Expressing the Caspase 6 Fragment of Mutant Huntingtin. Journal of Neuroscience, 2012, 32, 183-193.	3.6	49
31	trans-(â˜)-Îµ-Viniferin Increases Mitochondrial Sirtuin 3 (SIRT3), Activates AMP-activated Protein Kinase (AMPK), and Protects Cells in Models of Huntington Disease. Journal of Biological Chemistry, 2012, 287, 24460-24472.	3.4	192
32	Striatal neuronal loss correlates with clinical motor impairment in Huntington's disease. Movement Disorders, 2012, 27, 1379-1386.	3.9	71
33	Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets. Nature Medicine, 2012, 18, 153-158.	30.7	300
34	Interrogation of brain miRNA and <scp>mRNA</scp> expression profiles reveals a molecular regulatory network that is perturbed by mutant huntingtin. Journal of Neurochemistry, 2012, 123, 477-490.	3.9	57
35	Spatiotemporal mapping of brain atrophy in mouse models of Huntington's disease using longitudinal in vivo magnetic resonance imaging. NeuroImage, 2012, 60, 2086-2095.	4.2	25
36	Structural MRI detects progressive regional brain atrophy and neuroprotective effects in N171-82Q Huntington's disease mouse model. NeuroImage, 2011, 56, 1027-1034.	4.2	48

#	Article	IF	Citations
37	Peroxisome-Proliferator-Activated Receptor Gamma Coactivator 1 Â Contributes to Dysmyelination in Experimental Models of Huntington's Disease. Journal of Neuroscience, 2011, 31, 9544-9553.	3.6	117
38	Baicalein reduces E46K Î±â€synuclein aggregation in vitro and protects cells against E46K Î±â€synuclein toxicity in cell models of familiar Parkinsonism. Journal of Neurochemistry, 2010, 114, 419-429.	3.9	76
39	Longitudinal characterization of brain atrophy of a Huntington's disease mouse model by automated morphological analyses of magnetic resonance images. NeuroImage, 2010, 49, 2340-2351.	4.2	84
40	Potential Therapeutic Targets for Neurodegenerative Diseases: Lessons Learned from Calorie Restriction. Current Drug Targets, 2010, 11, 1281-1292.	2.1	17
41	Altered Calcium Homeostasis and Mitochondrial Dysfunction in Cortical Synaptic Compartments of Presenilin-1 Mutant Mice. Journal of Neurochemistry, 2008, 72, 1030-1039.	3.9	144
42	Tiagabine is neuroprotective in the N171-82Q and R6/2 mouse models of Huntington's disease. Neurobiology of Disease, 2008, 30, 293-302.	4.4	44
43	Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington's disease. Neurobiology of Disease, 2008, 30, 312-322.	4.4	129
44	The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model. Experimental Neurology, 2008, 210, 154-163.	4.1	152
45	Leptin-mediated Cell Survival Signaling in Hippocampal Neurons Mediated by JAK STAT3 and Mitochondrial Stabilization. Journal of Biological Chemistry, 2008, 283, 1754-1763.	3.4	178
46	Single Particle Characterization of Iron-induced Pore-forming Î±-Synuclein Oligomers. Journal of Biological Chemistry, 2008, 283, 10992-11003.	3.4	204
47	Multifunctional tellurium molecule protects and restores dopaminergic neurons in Parkinson's disease models. FASEB Journal, 2007, 21, 1870-1883.	0.5	66
48	Bioactivity Profiling with Parallel Mass Spectrometry Reveals an Assemblage of Green Tea Metabolites Affording Protection against Human Huntingtin and Î±-Synuclein Toxicity. Journal of Agricultural and Food Chemistry, 2007, 55, 9450-9456.	5.2	16
49	Compounds blocking mutant huntingtin toxicity identified using a Huntington's disease neuronal cell model. Neurobiology of Disease, 2005, 20, 500-508.	4.4	41
50	Paroxetine retards disease onset and progression in Huntingtin mutant mice. Annals of Neurology, 2004, 55, 590-594.	5.3	84
51	Prophylactic activation of neuroprotective stress response pathways by dietary and behavioral manipulations. NeuroRx, 2004, 1, 111-116.	6.0	119
52	Meal size and frequency affect neuronal plasticity and vulnerability to disease: cellular and molecular mechanisms. Journal of Neurochemistry, 2003, 84, 417-431.	3.9	244
53	Dietary restriction normalizes glucose metabolism and BDNF levels, slows disease progression, and increases survival in huntingtin mutant mice. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 2911-2916.	7.1	391
54	Reversal of Behavioral and Metabolic Abnormalities, and Insulin Resistance Syndrome, by Dietary Restriction in Mice Deficient in Brain-Derived Neurotrophic Factor. Endocrinology, 2003, 144, 2446-2453.	2.8	166

#	Article	IF	Citations
55	Cellular and molecular mechanisms whereby dietary restriction extends healthspan: a beneficial type of stress. Advances in Cell Aging and Gerontology, 2003, 14, 87-103.	0.1	4
56	Folic acid and homocysteine in age-related disease. Ageing Research Reviews, 2002, 1, 95-111.	10.9	119
57	How does the brain control lifespan?. Ageing Research Reviews, 2002, 1, 155-165.	10.9	58
58	Neuroprotective and neurorestorative signal transduction mechanisms in brain aging: modification by genes, diet and behavior. Neurobiology of Aging, 2002, 23, 695-705.	3.1	89
59	Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. Journal of Neurochemistry, 2002, 80, 101-110.	3.9	361
60	Evidence that brain-derived neurotrophic factor is required for basal neurogenesis and mediates, in part, the enhancement of neurogenesis by dietary restriction in the hippocampus of adult mice. Journal of Neurochemistry, 2002, 82, 1367-1375.	3.9	850
61	Prostate Apoptosis Response-4 Production in Synaptic Compartments Following Apoptotic and Excitotoxic Insults. Journal of Neurochemistry, 2002, 72, 2312-2322.	3.9	87
62	Brain-derived neurotrophic factor mediates an excitoprotective effect of dietary restriction in mice. Journal of Neurochemistry, 2001, 76, 619-626.	3.9	173
63	Dietary Restriction Stimulates BDNF Production in the Brain and Thereby Protects Neurons Against Excitotoxic Injury. Journal of Molecular Neuroscience, 2001, 16, 1-12.	2.3	157
64	Progress in the Development of Caloric Restriction Mimetic Dietary Supplements. Rejuvenation Research, 2001, 4, 225-232.	0.2	15
65	Dietary Restriction Increases the Number of Newly Generated Neural Cells, and Induces BDNF Expression, in the Dentate Gyrus of Rats. Journal of Molecular Neuroscience, 2000, 15, 99-108.	2.3	343
66	Cellular and Molecular Mechanisms Underlying Perturbed Energy Metabolism and Neuronal Degeneration in Alzheimer's and Parkinson's Diseases. Annals of the New York Academy of Sciences, 1999, 893, 154-175.	3.8	326
67	Par-4: An Emerging Pivotal Player in Neuronal Apoptosis and Neurodegenerative Disorders. Journal of Molecular Neuroscience, 1999, 13, 17-30.	2.3	59
68	Participation of prostate apoptosis response-4 in degeneration of dopaminergic neurons in models of Parkinson's disease. Annals of Neurology, 1999, 46, 587-597.	5.3	108
69	Dietary restriction and 2-deoxyglucose administration improve behavioral outcome and reduce degeneration of dopaminergic neurons in models of Parkinson's disease. Journal of Neuroscience Research, 1999, 57, 195-206.	2.9	401
70	â€œApoptoticâ€•biochemical cascades in synaptic compartments: Roles in adaptive plasticity and neurodegenerative disorders. Journal of Neuroscience Research, 1999, 58, 152-166.	2.9	150
71	Dietary restriction and 2â€deoxyglucose administration improve behavioral outcome and reduce degeneration of dopaminergic neurons in models of Parkinson's disease. Journal of Neuroscience Research, 1999, 57, 195-206.	2.9	271